Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Nature BioTech SciCafe

Summary

Related Content

R&W Insurance Coverage for Healthcare Services Transactions

The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies

HHS to Create New Potential Medicare Pricing Models for Cell and Gene Therapy, Drugs Subject to Accelerated FDA Approval, and “High-Value” Generics

DOJ Revises Corporate Compliance Guidance to Take on Compensation Incentives and Communications Preservation — With a Continued Emphasis on Individual Accountability

A Recap of Resilience: Goodwin’s Life Sciences Practice

2022 Year in Review: Securities Litigation Against Life Sciences Companies

EMA Adopts Positive Opinion for Amgen’s Eculizumab Biosimilar Candidate BEKEMV®

DOJ Announces Nationwide Voluntary Corporate Self-Disclosure Policy in Effort to Standardize and Incentivize Timely Self-Reporting

The Inflation Reduction Act & Medicare Pricing for Drugs and Biologics

Moderna and Generation Bio Announce $76 Million Strategic Collaboration to Develop Non-Viral Genetic Medicines

Nicole Daley Honored by the 2023 Massachusetts Lawyers Weekly Excellence in the Law Awards

Goodwin named in Top 3 for US Private Equity Debt Deals in 2022

Goodwin Snags Tech and Life Sciences Litigation Trio (Commercial Dispute Resolution)

Goodwin Adds 3 IP Litigators In NY (Law360)

Goodwin Grows New York IP Litigation Practice by Three Partners (Bloomberg Law)

Goodwin Welcomes Leading Technology and Life Sciences Litigation Team in New York

Life Sciences